Allergan
In Howard Marks's portfolio · Oaktree Capital Management
Ticker AGN.PR
Not in the portfolio as of Q2 2026. Every quarter it shows up in a Oaktree Capital Management 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q2 2017 | Add 5% | 70,296 | 1.0% |
| Q1 2017 | Buy | 67,000 | 0.8% |
| Q2 2016 | Add 46% | 90,683 | 1.5% |
| Q1 2016 | Reduce 34% | 61,900 | 1.0% |
| Q4 2015 | Add 30% | 93,900 | 1.3% |
| Q3 2015 | Buy | 72,000 | 0.9% |
| Q3 2015 | Sell | 0 | |
| Q2 2015 | Buy | 71,000 | 0.9% |
| Q2 2015 | Sell | 0 | |
| Q1 2015 | Buy | 65,500 | 0.7% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.